Effects of DL-3-(5-benzimidazolyl)-2-methylalanine on brain and heart catecholamines-I. Depleting effects.
D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001545:Benserazide / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D002395:Catecholamines / Q000096:biosynthesis / Q000378:metabolism*; D004296:Dopa Decarboxylase / Q000378:metabolism; D005727:Ganglia, Spinal / Q000201:enzymology; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D001562:Benzimidazoles; D002395:Catecholamines; C006700:3-(5-benzimidazolyl)-2-methylalanine; D001545:Benserazide; D014446:Tyrosine 3-Monooxygenase; D004296:Dopa Decarboxylase; D000409:Alanine; D009638:Norepinephrine